Bionano Genomics reported third‑quarter 2025 revenue of $7.4 million, a 21 percent increase from $6.1 million in the same period last year and a $0.6 million beat over the consensus estimate of $6.8 million. The growth was driven by higher utilization of consumables and software among its core routine‑use customers, with a notable uptick in Japan where researchers are adopting optical genome mapping to tackle complex genetic questions.
The company did not disclose an earnings‑per‑share figure for the quarter, leaving analysts unable to determine whether the EPS beat or missed expectations. The consensus estimate for Q3 2025 EPS was $‑1.81, but without the actual number the beat/miss assessment remains incomplete.
Gross margin improved sharply to 46 percent on a non‑GAAP basis, up from 26 percent in Q3 2024. The expansion reflects a shift toward higher‑margin consumables and software, as well as disciplined cost control that reduced operating expenses by 40 percent to $9.7 million. The company’s focus on routine‑user utilization has also helped stabilize revenue streams and improve pricing power.
Flow‑cell sales reached 8,390 units in Q3 2025, a 7 percent year‑over‑year increase, indicating stronger instrument utilization and a growing customer base. While the report does not break down revenue by instrument, consumables, and software segments, it notes that consumables and software revenue rose 15 percent, underscoring the success of the strategic pivot toward recurring revenue.
Bionano reiterated its full‑year 2025 revenue guidance at $26 million to $30 million and projected Q4 revenue of $7.5 million to $7.9 million. The guidance reflects management’s confidence in sustained demand from routine users and the momentum generated by the new CMS Category I CPT code for optical genome mapping, which is expected to broaden reimbursement pathways.
After the earnings release, the company’s shares experienced a 6 percent jump in after‑hours trading, driven primarily by the revenue beat and the reaffirmation of full‑year guidance. Market participants viewed the results as evidence that the company’s strategic shift is yielding tangible financial improvements.
CEO Erik Holmlin emphasized that the quarter’s performance “validates the strategic shift toward driving consumables and software utilization among our existing routine‑use customers.” He added that the company remains focused on “sustainable growth as our business stabilizes,” highlighting the importance of disciplined operating expense management and margin expansion.
The company acknowledged a challenging market environment, noting that a prior year write‑down of aged receivables related to discontinued clinical service products still weighs on cash flow. However, the new CMS payment determination and the growth in Japan are seen as tailwinds that will support future revenue growth.
Overall, the earnings release demonstrates that Bionano’s transition to a consumables‑centric model is beginning to pay off, with stronger margins, disciplined costs, and a clear path to meeting its revenue guidance. The company’s focus on routine‑user utilization and expanding reimbursement options positions it for continued growth in the optical genome mapping market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.